These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 21335051)

  • 1. Gold implants and increased expression of metallothionein-I/II as a novel hypothesized therapeutic approach for autism.
    Ghanizadeh A
    Toxicology; 2011 Apr; 283(1):63-4. PubMed ID: 21335051
    [No Abstract]   [Full Text] [Related]  

  • 2. Hydrogen as a novel hypothesized emerging treatment for oxidative stress in autism.
    Ghanizadeh A
    Eur Rev Med Pharmacol Sci; 2012 Sep; 16(9):1313-4. PubMed ID: 23047522
    [No Abstract]   [Full Text] [Related]  

  • 3. Increased excretion of a lipid peroxidation biomarker in autism.
    Ming X; Stein TP; Brimacombe M; Johnson WG; Lambert GH; Wagner GC
    Prostaglandins Leukot Essent Fatty Acids; 2005 Nov; 73(5):379-84. PubMed ID: 16081262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxidative pathways as a drug target for the treatment of autism.
    Villagonzalo KA; Dodd S; Dean O; Gray K; Tonge B; Berk M
    Expert Opin Ther Targets; 2010 Dec; 14(12):1301-10. PubMed ID: 20954799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxidative stress in autism.
    McGinnis WR
    Altern Ther Health Med; 2005; 11(1):19. PubMed ID: 15712760
    [No Abstract]   [Full Text] [Related]  

  • 6. A zinc(II)-glycine complex is an effective inducer of metallothionein and removes oxidative stress.
    Masaki H; Ochiai Y; Okano Y; Yagami A; Akamatsu H; Matsunaga K; Sakurai H; Suzuki K
    J Dermatol Sci; 2007 Jan; 45(1):73-5. PubMed ID: 17045783
    [No Abstract]   [Full Text] [Related]  

  • 7. May lovastatin target both autism and epilepsy? A novel hypothesized treatment.
    Ghanizadeh A
    Epilepsy Behav; 2011 Feb; 20(2):422. PubMed ID: 21269887
    [No Abstract]   [Full Text] [Related]  

  • 8. Measurement of selected ions related to oxidative stress and energy metabolism in Saudi autistic children.
    El-Ansary A; Al-Daihan S; Al-Dbass A; Al-Ayadhi L
    Clin Biochem; 2010 Jan; 43(1-2):63-70. PubMed ID: 19781542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of metallothionein and antibodies to metallothionein in normal and autistic children having exposure to vaccine-derived thimerosal.
    Singh VK; Hanson J
    Pediatr Allergy Immunol; 2006 Jun; 17(4):291-6. PubMed ID: 16771783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-6 deficiency leads to reduced metallothionein-I+II expression and increased oxidative stress in the brain stem after 6-aminonicotinamide treatment.
    Penkowa M; Hidalgo J
    Exp Neurol; 2000 May; 163(1):72-84. PubMed ID: 10785446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The regulation of metallothionein expression and its relationship to zinc].
    Chen WQ; Cheng YY
    Sheng Li Ke Xue Jin Zhan; 2003 Apr; 34(2):150-3. PubMed ID: 12889151
    [No Abstract]   [Full Text] [Related]  

  • 12. Theoretical aspects of the study of benzodiazepine receptors in infantile autism.
    Garreau B; Herry D; Zilbovicius M; Samson Y; Guerin P; Lelord G
    Acta Paedopsychiatr; 1993; 56(2):133-8. PubMed ID: 8135112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel therapeutic targets for autism.
    Theoharides TC; Doyle R; Francis K; Conti P; Kalogeromitros D
    Trends Pharmacol Sci; 2008 Aug; 29(8):375-82. PubMed ID: 18606459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered vascular phenotype in autism: correlation with oxidative stress.
    Yao Y; Walsh WJ; McGinnis WR; Praticò D
    Arch Neurol; 2006 Aug; 63(8):1161-4. PubMed ID: 16908745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxidative stress may mediate association of stereotypy and immunity in autism, a novel explanation with clinical and research implications.
    Ghanizadeh A
    J Neuroimmunol; 2011 Mar; 232(1-2):194-5. PubMed ID: 21075458
    [No Abstract]   [Full Text] [Related]  

  • 16. Cyproheptadine in the treatment of autistic disorder: a double-blind placebo-controlled trial.
    Akhondzadeh S; Erfani S; Mohammadi MR; Tehrani-Doost M; Amini H; Gudarzi SS; Yasamy MT
    J Clin Pharm Ther; 2004 Apr; 29(2):145-50. PubMed ID: 15068403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxidative stress in autism: increased lipid peroxidation and reduced serum levels of ceruloplasmin and transferrin--the antioxidant proteins.
    Chauhan A; Chauhan V; Brown WT; Cohen I
    Life Sci; 2004 Oct; 75(21):2539-49. PubMed ID: 15363659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Infantile autism and drug therapy].
    Kehrer HE
    Bibl Psychiatr; 1978; (157):91-7. PubMed ID: 348194
    [No Abstract]   [Full Text] [Related]  

  • 19. Studies on the mechanism of early onset macular degeneration in cynomolgus monkeys. II. Suppression of metallothionein synthesis in the retina in oxidative stress.
    Nicolas MG; Fujiki K; Murayama K; Suzuki MT; Shindo N; Hotta Y; Iwata F; Fujimura T; Yoshikawa Y; Cho F; Kanai A
    Exp Eye Res; 1996 Apr; 62(4):399-408. PubMed ID: 8795458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of children with autism with intravenous immunoglobulin.
    Gupta S
    J Child Neurol; 1999 Mar; 14(3):203-5. PubMed ID: 10190273
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.